**NEW DATE: Tuesday, January 21 @ 10 am PT** ME/CFS has a broad spectrum of severity, with some able to work while others require total care and support. People living […]
Join us for a webinar on April 29 from 3-4 pm PT / 6-7 pm ET with Solve Ramsay Research Grant winners Liisa K. Selin, MD, PhD, and Anna Gil, […]
One of the cornerstones of our annual Advocacy Week program is the EmPOWER M.E. roundtable. Panels of patient advocates, professionals, and scientists share their expertise on topics relevant to the […]
Dr. Akiko Iwasaki (Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University) is the first recipient of Solve’s ME/CFS Catalyst Award in support of her study, […]
Simmaron Research is the second recipient of Solve’s ME/CFS Catalyst Award in support of its study,” “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” Read a preprint […]
Chronic illnesses such as myalgic encephalomyelitis (ME) and Long COVID, which lack clinical biomarkers, present challenges around diagnosis, symptom reporting, and monitoring. That’s why the unhide® Solve Together Unified Platform–which […]
For the first time, scientists have developed a simple, accurate blood test that can potentially identify Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) — a long-term, debilitating condition that affects […]
Caring for someone with ME/CFS is an act of deep love–and preparation is one of the most meaningful ways to protect their future. Hosted by Solve M.E. Director of Advocacy […]
Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the natural GLP-1 hormone, which helps regulate insulin levels. Thus, these medicines help control blood sugar in people with Type 2 diabetes and promote substantial weight loss for individuals with a high body mass index (BMI) by slowing digestion, reducing appetite, […]
Dr. Liisa Selin, Dr. Ayano Kohlgruber, and Dr. Roshan Kumar received a Solve ME/CFS Catalyst Award for their study searching for the exact proteins recognized by T-cell receptors from a person with ME/CFS and a person with Long Covid. These disease-associated T cells include “exhausted” CD8+ T cells and “double-positive” CD4+/CD8+ T cells (which are […]
The DecodeME Project is the largest genetic study of ME/CFS conducted to date and has identified eight genetic signals where people with ME/CFS tend to differ from those without, linked to the immune and nervous systems. These landmark findings reflect the lived experience of thousands of people with ME/CFS, providing validation and exciting new avenues for […]
In 2025, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study, “Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” The study hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other […]
